HYPOGONADISM IN METABOLIC SYNDROME PATIENTS
Journal Title: Romanian Journal of Diabetes Nutrition and Metabolic Diseases - Year 2011, Vol 18, Issue 1
Abstract
Introduction. Previous studies have shown a high prevalence of low levels of the endogenous sexual hormones in patients with metabolic syndrome (MetS). The aim of this study was to analyze the prevalence of hypogonadism in MetS patients. Materials and Methods. We analyzed the relationship between testosterone levels and components of metabolic syndrome in 381 patients. These patients were divided into two groups: group A – patients with metabolic syndrome (MetS) and hypogonadism (MetS+T) and group B – patients with metabolic syndrome without hypogonadism (MetS-T). Overweight was defined as BMI 26-29.9kg/m2. Obesity was defined as BMI≥30 kg/m2. Male hypogonadism or androgen deficiency has been defined as a maximum level of total testosterone up to 3 ng/ml. Results. There were no significant age differences between groups (59.8±8.38 versus 58.31±7.47 years p=0.06). Prevalence of hypogonadism in metabolic syndrome patients was 33.5% (n=128). There were no significant differences between groups in terms of body weight, waist circumference, hip circumference, BMI and blood pressure between groups (all p>0.05). Patients with hypogonadism had significantly higher levels of triglycerides, FPI, HOMA-IR (all p<0.05) and smaller HDL-cholesterol and SHBG (all p<0.05). There was a significant decline in testosterone concentration with increase in age and BMI. 88.3% of the diabetic patients (n=113) had hypogonadism (p=0.0001). Hypogonadism was present in 25% patients (n=32) with 3 components of MetS, 43.8% (n=56) patients with 4 componets of MetS and in 31.2% (n=40) patients with 5 components of MetS (p=0.0001). Conclusions. Hypogonadism is a common occurrence in subjects with MetS. Males with MetS with or without diabetes have lower serum testosterone. Patients with MetS should be investigated for clinical and biochemical signs of hypogonadism and patients with hypogonadism should be investigated for signs of metabolic syndrome.
Authors and Affiliations
Florin Rusu, Emilia Rusu, Gabriela Radulian, Georgiana Enache, Mariana Jinga, Viorel Jinga, Carmen Radu, Dan Mischianu, Dan Mircea Cheţa
Keywords
Related Articles
- EP ID EP155377
- DOI -
- Views 103
- Downloads 0
THERAPY WITH GLP-1 AGONISTS AND DIPEPTIDYL-PEPTIDASE IV INHIBITORS IN TYPE 2 DIABETES MELLITUS
Since type 2 diabetes is increasing and most patients do not reach their therapeutic goals, novel treatment options are needed. The novel therapeutic options for type 2 diabetes mellitus (Type 2 DM); respectively those b...
SODIUM-GLUCOSE TRANSPORTER 2 INHIBITION – A POTENTIAL OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Glucose homeostasis is maintained by the balanced actions of glucose absorption, gluconeogenesis, glycogenolysis, glucose consumption, glucose excretion and glucose reabsorption. The human kidney is involved in glucose r...
HEPATIC STEATOSIS IN PATIENTS WITH HEPATITIS C
Aims: The aims of this study was to indentify independent predictive factors of liver steatosis in patients with hepatitis C and to examine the correlations between ultrasound-diagnosed HS and anthropometric, clinical, b...
PANCREAS TRANSPLANTATION – BENEFITS AND RISKS FOR DIABETIC PATIENTS
Pancreas transplantation is considered a valuable therapeutic option in diabetic patients, either alone or combined with renal allografts in transplant candidates with imminent or established end-stage renal disease. Imp...
LET’S DISCUSS ABOUT SOME ASPECTS OF THE DIABETES EPIDEMIOLOGY IN ROMANIA